...
首页> 外文期刊>Journal of Korean Neurosurgical Society >Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas : Single Institutional Experience of 14 Consecutive Cases
【24h】

Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas : Single Institutional Experience of 14 Consecutive Cases

机译:致甲状腺刺激激素分泌垂体腺瘤:连续14例的单一制度体验

获取原文
           

摘要

Objective Thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (PA) is an extremely rare functioning form of PA that accounts for 0.7–2% of all such cases. The previously reported outcomes of the surgical removal of TSH-PA are poor. Owing to its extremely low incidence, most available reports on TSH-PA are case reports or small case series. Thus, we investigated the clinical and endocrinological outcomes of surgically treated TSH-PA through our institutional series. Methods We retrospectively reviewed 14 consecutive cases of surgically treated TSH-PA, focusing on the clinical, radiological, surgical, and endocrinological data. Results There were seven male (50%) and seven female (50%) patients. The mean age was 42.5 years (range, 19–63). The mean tumor size was 16.6 mm (range, 4–30). Optic chiasm compression was noted in six patients (42.9%), and no patient showed cavernous sinus invasion. Thirteen of 14 patients (92.8%) underwent transnasal transsphenoidal approach (TSA), and one patient underwent TSA followed by transcranial approach for residual tumor removal. Thirteen of 14 patients (92.8%) showed endocrinological remission; all patients who experienced remission showed subnormal levels of TSH (0.4 μU/mL) on postoperative day 2. Recurrence occurred in two patients (14.2%). One patient underwent subsequent revision transnasal TSA for recurrent tumor removal, and the other patient underwent gamma knife radiosurgery for recurrence. Conclusion Surgical treatment showed excellent surgical outcomes. The TSH level in the immediate postoperative period may be a predictor for endocrinological remission.
机译:目的甲状腺刺激激素(TSH) - 分泌垂体腺瘤(PA)是一种极其罕见的PA,占所有此类病例的0.7-2%。先前报告的TSH-PA手术切除的结果差。由于其极低的发病率,有关TSH-PA的最多可用的报告是报告或小写系列。因此,我们通过我们的机构系列调查了手术治疗的TSH-PA的临床和内分泌结果。方法我们回顾性地审查了三种手术治疗TSH-PA病例,专注于临床,放射性,外科和内分泌数据。结果有七种男性(50%)和7名女性(50%)患者。平均年龄为42.5岁(范围,19-63)。平均肿瘤大小为16.6毫米(范围,4-30)。六名患者(42.9%)注意到视神经钩伤压缩,患者没有患者展示海绵窦入侵。 14名患者(92.8%)的14例(92.8%)进行了跨营晶状体方法(TSA),一名患者接受了一名患者,然后进行了颅内肿瘤去除的经颅方法。 14名患者(92.8%)显示内分泌缓解;所有经历缓解的患者在术后第2天表明TSH(<0.4μu/ ml)的亚型水平2.两次患者发生复发(14.2%)。一名患者接受后续修正群TSA用于复发性肿瘤的去除,另一种患者接受γ刀放射外科进行复发。结论外科治疗表现出优异的手术结果。直接术后时期的TSH水平可能是内分泌缓解的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号